v3.25.2
Note 10 - Segments
6 Months Ended
Jun. 30, 2025
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

10. Segments

 

The Company’s CODM is its Chief Executive Officer. The Company’s CODM evaluates the operating results of the Company’s reportable segments based on cash used in operations, revenues and net income (loss).

 

The Company follows the accounting guidance of ASC 280, Segment Reporting (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the CODM organizes the segments within an enterprise for making operating decisions and assessing performance. While the Company’s results of operations are primarily reviewed on a consolidated basis, the CODM manages the enterprise in two reportable segments, each with different operating and potential revenue generating characteristics.

 

The Company has two operating and reportable segments: (i) Regenerative Biotech focused on the development of regenerative medicine treatments with operations currently in the United States and (ii) Consumer Health Products relating to consumer health products with operations currently in Asia. All of the Company’s revenue was generated in Asia for the three and six months ended June 30, 2025 and 2024. The following tables represent selected financial information for our segments:

 

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
  

2025

  

2024

  

2025

  

2024

 

Product revenue:

                

Regenerative Biotech

 $  $  $  $ 

Consumer Health Products

  317   56   362   113 

Total

 $317  $56  $362  $113 
                 

Net loss:

                

Regenerative Biotech

 $(1,842) $(2,320) $(3,511) $(4,255)

Consumer Health Products

  19   (178)  29   (273)

Total

 $(1,823) $(2,498) $(3,482) $(4,528)

 

  June 30,  December 31, 
  

2025

  

2024

 

Cash and cash equivalents:

        

Regenerative Biotech

 $591  $2,405 

Consumer Health Products

  195   81 

Total

 $786  $2,486 
         

Total assets:

        

Regenerative Biotech

 $1,786  $3,978 

Consumer Health Products

  351   464 

Total

 $2,137  $4,442